CARLSBAD, Calif., Nov. 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:
What: Isis' Analyst & Investor Day
When: Tuesday, November 13, 2007, at 9:00 a.m. ET / 6:00 a.m. PT
How: Live on the Internet. Simply log onto our web site listed
Contacts: Kristina Lemonidis
Associate Director, Investor Relations
Amy Blackley, Ph.D.
Manager, Corporate Communications
If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at http://www.isispharm.com.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop novel
drugs for its product pipeline and for its partners. The Company has
successfully commercialized the world's first antisense drug and has 18
drugs in development. Isis' drug development programs are focused on
treating cardiovascular and metabolic diseases. Isis' partners are
developing drugs for a wide variety of diseases. Ibis Biosciences, Inc.,
Isis' wholly owned subsidiary, is developing and commercializing the Ibis
T5000(TM) Biosensor System, a revolutionary system to identify infectious
organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint
venture focused on the discovery, development and commercialization of
microRNA therapeutics. As an innovator in RNA-based drug discovery and
development, Isis is the
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved